The Infiny research teams gathered on Monday, May 26, in Nancy to share updates on their progress within the various work packages of the scientific program. They also worked collaboratively to identify potential synergies across the fundamental, translational, and clinical research components of the IHU.
The session was held under the guidance of Benoît Chassaing, Scientific Director for Basic and Translational Research, and in the presence of Catherine Schuster, Scientific Advisor for Inserm Grand Est; Chantal Boulanger, Director of the Inserm Thematic Institute of Physiology, Metabolism and Nutrition (PMN); Alain Hehn, Vice-Chairman of the Scientific Council at Université de Lorraine; and Christian Rabaud, Acting Director of IHU Infiny. Each task leader was invited to present the objectives, needs, and constraints of their respective projects, all aimed at advancing our understanding of the mechanisms underlying inflammatory bowel disease (IBD).
This collective effort is key to implementing an integrated research strategy that serves patients—by identifying opportunities to pool resources, encourage methodological cross-fertilization, explore the development of preclinical platforms, and define the challenges and requirements related to building and monitoring the Infiny cohort.
The discussions helped shape three main strategic priorities: preventing IBD by studying environmental factors; developing targeted, personalized therapies; and creating advanced experimental models.
The IHU’s International Scientific Committee will also be consulted to provide expert input on improving diagnosis, advancing targeted treatments, and personalizing care.
Discover our ongoing research projects.
